MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591361 | Name: Lansoprazole sulfone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.

Chemical Structure

Lansoprazole sulfone
Lansoprazole sulfone
CAS#131926-99-3

Theoretical Analysis

MedKoo Cat#: 591361

Name: Lansoprazole sulfone

CAS#: 131926-99-3

Chemical Formula: C16H14F3N3O3S

Exact Mass: 385.0708

Molecular Weight: 385.36

Elemental Analysis: C, 49.87; H, 3.66; F, 14.79; N, 10.90; O, 12.46; S, 8.32

Price and Availability

Size Price Availability Quantity
10mg USD 480.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Lansoprazole sulfone; AG-1813; AG 1813; AG1813
IUPAC/Chemical Name
1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfonyl)-
InChi Key
TVMJMCGRSSSSDJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H14F3N3O3S/c1-10-13(20-7-6-14(10)25-9-16(17,18)19)8-26(23,24)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
SMILES Code
O=S(C1=NC2=CC=CC=C2N1)(CC3=NC=CC(OCC(F)(F)F)=C3C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
A metabolite of lansoprazole.
In vitro activity:
Lansoprazole induced the expression of heme oxygenase-1 (HO-1) on rat gastric epithelial cells (RGM-1 cells), and exerted anti-inflammatory effect on the dependent of HO-1 expression. Reference: J Clin Biochem Nutr. 2009 Jul;45(1):9-13. https://pubmed.ncbi.nlm.nih.gov/19590701/
In vivo activity:
The present study investigates the potential of lansoprazole (a proton pump inhibitor and agonist of liver x receptors) in experimental dementia of AD type. Streptozotocin [STZ, 3 mg/kg, injected intracerebroventricular (i.c.v), and high fat diet (HFD, administered for 90 days)] were used to induce dementia in separate groups of Swiss mice. Lansoprazole treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations. It also prevented HFD-induced rise in the cholesterol level. Reference: PLoS One. 2013 Jul 31;8(7):e70487. https://pubmed.ncbi.nlm.nih.gov/23936214/
Solvent mg/mL mM
Solubility
DMF 30.0 77.85
DMSO 30.0 77.85
DMSO:PBS (pH 7.2) (1:1) 0.5 1.30
Ethanol 5.0 12.97
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 385.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Cheng Z, Liu Y, Ma M, Sun S, Ma Z, Wang Y, Yu L, Qian X, Sun L, Zhang X, Liu Y, Wang Y. Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways. Mol Med. 2022 Feb 19;28(1):21. doi: 10.1186/s10020-022-00448-x. PMID: 35183103; PMCID: PMC8858482. 2. Takagi T, Naito Y, Yoshikawa T. The expression of heme oxygenase-1 induced by lansoprazole. J Clin Biochem Nutr. 2009 Jul;45(1):9-13. doi: 10.3164/jcbnSR09-28. Epub 2009 Jun 30. PMID: 19590701; PMCID: PMC2704331. 3. Sodhi RK, Singh N. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. doi: 10.1371/journal.pone.0070487. PMID: 23936214; PMCID: PMC3729942. 4. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. doi: 10.1016/j.bcp.2011.02.009. Epub 2011 Mar 1. PMID: 21371447.
In vitro protocol:
1. Cheng Z, Liu Y, Ma M, Sun S, Ma Z, Wang Y, Yu L, Qian X, Sun L, Zhang X, Liu Y, Wang Y. Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways. Mol Med. 2022 Feb 19;28(1):21. doi: 10.1186/s10020-022-00448-x. PMID: 35183103; PMCID: PMC8858482. 2. Takagi T, Naito Y, Yoshikawa T. The expression of heme oxygenase-1 induced by lansoprazole. J Clin Biochem Nutr. 2009 Jul;45(1):9-13. doi: 10.3164/jcbnSR09-28. Epub 2009 Jun 30. PMID: 19590701; PMCID: PMC2704331.
In vivo protocol:
1. Sodhi RK, Singh N. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. doi: 10.1371/journal.pone.0070487. PMID: 23936214; PMCID: PMC3729942. 2. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. doi: 10.1016/j.bcp.2011.02.009. Epub 2011 Mar 1. PMID: 21371447.
1: Zhang D, Zhang Y, Liu M, Wang X, Yang M, Han J, Liu H. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):209-15. doi: 10.1007/s13318-012-0115-8. Epub 2012 Dec 11. PubMed PMID: 23229306. 2: Zhang D, Yang M, Liu M, Zhang Y, Wang X, Xiao X, Liu H. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. Xenobiotica. 2012 Nov;42(11):1156-62. doi: 10.3109/00498254.2012.687119. Epub 2012 May 21. PubMed PMID: 22612620. 3: Zhang D, Wang X, Yang M, Wang G, Liu H. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica. 2011 Jun;41(6):511-7. doi: 10.3109/00498254.2011.559556. Epub 2011 Apr 27. Erratum in: Xenobiotica. 2011 Sep;41(9):836. PubMed PMID: 21521077. 4: Xu HR, Chen WL, Li XN, Chu NN. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol. 2010 Aug;48(8):947-52. doi: 10.3109/13880200903300220. PubMed PMID: 20673183. 5: Yanagida Y, Watanabe M, Takeba Y, Kumai T, Matsumoto N, Hayashi M, Suzuki S, Kinoshita Y, Kobayashi S. Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. Biol Pharm Bull. 2009 Aug;32(8):1422-6. PubMed PMID: 19652384. 6: Song M, Gao X, Hang TJ, Wen AD. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. Curr Ther Res Clin Exp. 2009 Jun;70(3):228-39. doi: 10.1016/j.curtheres.2009.05.002. PubMed PMID: 24683233; PubMed Central PMCID: PMC3967358. 7: Song M, Gao X, Hang T, Wen A. Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2008 Dec 1;48(4):1181-6. doi: 10.1016/j.jpba.2008.08.034. Epub 2008 Sep 9. PubMed PMID: 18945568. 8: Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. Xenobiotica. 2006 Jan;36(1):95-102. PubMed PMID: 16507515. 9: Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005 Jul;60(1):61-8. PubMed PMID: 15963095; PubMed Central PMCID: PMC1884909. 10: Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9. PubMed PMID: 15752376; PubMed Central PMCID: PMC1884793. 11: Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):309-14. PubMed PMID: 15664363. 12: Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004 Nov;44(11):1223-9. PubMed PMID: 15496639. 13: Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8. Epub 2004 Sep 23. PubMed PMID: 15448955. 14: Miura M, Tada H, Suzuki T. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):389-95. PubMed PMID: 15081934. 15: Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003 Mar 28;278(13):10993-1001. Epub 2003 Jan 15. PubMed PMID: 12529378. 16: Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002 Jul;72(1):33-43. PubMed PMID: 12152002. 17: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol. 2001 Dec;57(10):709-15. PubMed PMID: 11829200. 18: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes. J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):127-33. PubMed PMID: 11419737. 19: Masa K, Hamada A, Arimori K, Fujii J, Nakano M. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. Biol Pharm Bull. 2001 Mar;24(3):274-7. PubMed PMID: 11256484. 20: Masa K, Arimori K, Nakayama T, Miyamoto S, Fujii J, Nakano M. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. Biol Pharm Bull. 1999 May;22(5):504-9. PubMed PMID: 10375172.